All About Allergies

1. Allergic diseases are rising rapidly due to environmental shifts, not just genetics.

While many people believe these diseases did not exist in the past, there is ample evidence that people have suffered from several conditions, such as food allergies and asthma, since antiquity.

Environmental drivers. While genetics predispose individuals to atopy, the modern allergy epidemic is primarily propelled by rapid environmental and lifestyle changes. The "Old Friends" hypothesis suggests that our reduced exposure to diverse, harmless microbes in early life disrupts immune regulation, while rising global temperatures and carbon dioxide levels have extended pollen seasons and increased pollen potency.

Botanical sexism myth. The viral theory of "botanical sexism"—the idea that cities only plant male trees to avoid messy seeds, thereby flooding the air with pollen—is largely a myth, as most urban trees possess both male and female reproductive organs. Instead, the true culprit is climate change, which is projected to start pollen seasons up to forty days earlier and increase pollen counts by 40 percent by the year 2100.

Key environmental factors:

• Extended pollen seasons due to fewer freezing days
• Increased pollen protein concentration driven by elevated CO2
• Reduced microbial diversity from urban living and cesarean births
• Heightened airway sensitivity triggered by modern air pollutants

2. The immune system's Th2 pathway and mast cells drive most allergic hypersensitivities.

Th2 cells release IL-4 and IL-13, which are cytokines that cause B cells to produce IgE antibodies.

Immune system pathways. Allergic reactions are primarily Type I hypersensitivity responses driven by the adaptive immune system's T-helper type 2 (Th2) cells. These cells release specific chemical messengers, or cytokines (such as IL-4, IL-5, and IL-13), which instruct B cells to produce IgE antibodies that bind to the surface of mast cells and basophils, sensitizing the body to harmless environmental proteins.

Mast cell degranulation. Upon subsequent exposure, the allergen cross-links the IgE antibodies on mast cells, triggering a process called degranulation. This rapid release of pre-formed chemical mediators, primarily histamine, leukotrienes, and prostaglandins, causes blood vessels to widen and smooth muscles to contract.

Key chemical mediators:

• Histamine: Causes itching, hives, swelling, and bronchoconstriction
• Leukotrienes: Promote prolonged airway narrowing and mucus production
• Prostaglandins: Drive vasodilation and local tissue inflammation
• Tryptase: Serves as a measurable blood marker for mast cell activation

3. Allergy testing measures sensitization, which does not automatically equal clinical allergy.

The size of the wheal on a skin test or the amount of specific IgE antibody measured in a blood test only tells us how likely a reaction may be.

Sensitization vs. allergy. A positive skin prick or blood IgE test only indicates that the immune system has created antibodies to a substance, a state known as sensitization. It does not guarantee that eating the food or inhaling the allergen will cause a physical reaction. Because food allergy skin tests have a high false-positive rate (with a specificity of only about 50 percent), ordering large panel tests without a matching clinical history often leads to unnecessary and harmful food avoidance.

Testing modalities. Skin prick testing remains the preferred initial diagnostic tool because it is rapid, highly sensitive, and provides immediate visual results in the clinic. Blood testing (measuring serum-specific IgE) is utilized when skin testing is unfeasible due to skin conditions like dermographism or the inability to stop antihistamines.

Diagnostic considerations:

• Skin prick tests: High sensitivity but prone to false positives for foods
• Intradermal tests: Used for environmental allergens and penicillin when prick tests are negative
• Component-resolved diagnostics: Pinpoints specific proteins to assess systemic reaction risks
• Oral food challenges: The absolute gold standard for diagnosing true clinical food allergies

4. Early allergen introduction is crucial to preventing lifelong food allergies.

Earlier introduction of peanuts reduced the risk of developing a peanut allergy by 81 percent.

The LEAP breakthrough. For decades, pediatric guidelines mistakenly recommended delaying the introduction of highly allergenic foods like peanuts, eggs, and fish to infants. However, landmark clinical trials like the Learning Early About Peanut Allergy (LEAP) study proved that introducing these foods between four and eleven months of age dramatically trains the immune system toward tolerance.

The dual-exposure hypothesis. This paradigm suggests that if an infant's first exposure to a food allergen occurs through disrupted skin (such as eczema), the immune system treats it as a threat and sensitizes the body. Conversely, early oral consumption introduces the allergen to the gut-associated lymphoid tissue (GALT), where regulatory T cells promote immune tolerance.

Key prevention strategies:

• Introduce diverse, age-appropriate allergenic foods starting around six months
• Ensure active eczema is aggressively treated to maintain a healthy skin barrier
• Avoid unnecessary food elimination diets, which can cause a loss of existing tolerance
• Consult an allergist for supervised in-office introductions if the infant is deemed high-risk

5. Chronic rhinosinusitis and asthma are closely linked inflammatory airway diseases.

Roughly one in five people living with CRS have asthma, and many of these individuals experience symptoms of depression.

The united airway. The upper and lower respiratory tracts are anatomically and immunologically connected, meaning that inflammation in the nasal passages directly impacts lung health. Chronic rhinosinusitis (CRS)—defined as sinus inflammation lasting twelve weeks or longer—frequently coexists with asthma, and poorly controlled sinus disease is a primary driver of severe asthma exacerbations.

Nasal polyps and AERD. In many cases, chronic sinus inflammation leads to the growth of noncancerous, grape-like masses called nasal polyps, which block the sinus openings (ostia) and destroy the sense of smell. A severe subset of this condition is Aspirin-Exacerbated Respiratory Disease (AERD), a triad of asthma, nasal polyps, and severe respiratory reactions to aspirin or other NSAIDs.

Clinical features of airway disease:

• Impaired mucociliary clearance leading to recurrent bacterial sinus infections
• Postnasal drip triggering chronic coughing and nighttime asthma symptoms
• Nasal polyps causing anosmia (loss of smell) and chronic congestion
• Bronchospasm requiring rescue bronchodilators like albuterol to open airways

6. Eczema is a skin barrier defect that requires a "soak and seal" routine rather than food elimination.

A food elimination diet in a child with eczema may increase the risk of developing a food allergy.

Skin barrier dysfunction. Eczema (atopic dermatitis) is primarily a genetic defect in the skin barrier—often involving a deficiency in the protein filaggrin, which acts as the "mortar" holding skin cells together. When this barrier is compromised, moisture escapes, and environmental irritants and allergens easily penetrate the skin, triggering a chronic Th2-mediated inflammatory response.

The "soak and seal" method. Because eczema is a structural skin issue rather than a food allergy, treating it requires restoring the skin barrier rather than eliminating foods. The cornerstone of daily management is the "soak and seal" routine: bathing daily in lukewarm water for ten minutes, lightly patting dry, immediately applying prescription topical medications, and sealing the moisture with a thick, fragrance-free ointment or cream.

Effective eczema therapies:

• Daily lukewarm baths followed by immediate application of thick moisturizers
• Dilute bleach baths to reduce Staphylococcus aureus colonization and skin infections
• Topical anti-inflammatory medications like steroids, calcineurin inhibitors, or JAK inhibitors
• Targeted biologic therapies like Dupixent for moderate-to-severe, uncontrolled cases

7. Contact dermatitis is a delayed T-cell reaction requiring patch testing and strict avoidance.

Unlike type I, II, and III hypersensitivities, delayed hypersensitivity reactions are not mediated by antibodies.

Delayed hypersensitivity. Contact dermatitis is a Type IV hypersensitivity reaction mediated by T cells rather than IgE antibodies, meaning symptoms typically take 24 to 72 hours to appear after exposure. It is divided into irritant contact dermatitis, caused by direct chemical damage to the skin, and allergic contact dermatitis, which requires prior sensitization to a specific chemical allergen.

Common chemical culprits. The most prevalent contact allergen globally is nickel, frequently found in jewelry, belt buckles, and jean buttons. Other common triggers include preservatives like formaldehyde, fragrances, topical antibiotics like neomycin, and acrylates used in modern gel nail polishes.

Diagnostic and management steps:

• Patch testing: Placing suspected allergens on the back for 48 hours to observe delayed reactions
• Strict avoidance of identified chemical triggers using allergen management databases
• Utilizing truly "fragrance-free" products rather than those labeled "unscented"
• Applying topical steroids or calcineurin inhibitors to calm active, localized rashes

8. Epinephrine is the only first-line treatment for life-threatening anaphylaxis.

Antihistamines such as diphenhydramine (Benadryl) or cetirizine (Zyrtec) should not be used instead of epinephrine to treat anaphylaxis.

Epinephrine first. Anaphylaxis is a rapid, systemic allergic reaction that can quickly become fatal if untreated. Epinephrine is the only medication capable of reversing the life-threatening features of anaphylaxis by constricting blood vessels to raise blood pressure, reducing airway swelling, and relaxing bronchial muscles to improve breathing.

The antihistamine myth. Many families mistakenly administer oral antihistamines like Benadryl during a severe reaction and wait to see if symptoms improve. This delay is highly dangerous; antihistamines only treat superficial skin symptoms like hives and itching, and they cannot stop airway obstruction or cardiovascular collapse.

Anaphylaxis emergency protocol:

• Inject epinephrine immediately into the outer thigh at the first sign of systemic symptoms
• Call emergency services (9-1-1) for professional medical transport and monitoring
• Place the patient flat on their back with their legs elevated to maintain blood flow to the heart
• Always carry two epinephrine auto-injectors (or the newly approved nasal spray, Neffy)

9. Most reported penicillin allergies are false labels that harm patient health outcomes.

Approximately 10 percent of Americans report having a penicillin allergy, but roughly 90 percent of these people do not have a true medication allergy.

The false allergy epidemic. Millions of patients carry a "penicillin allergy" label in their medical records based on childhood rashes that were actually caused by viral infections or non-allergic drug side effects. Furthermore, even true IgE-mediated penicillin allergies fade over time, with approximately 80 percent of patients outgrowing their sensitivity within ten years of the initial reaction.

Negative health consequences. Carrying a false penicillin allergy label forces doctors to prescribe alternative, broad-spectrum antibiotics. These alternative drugs are often less effective, more expensive, and significantly increase the patient's risk of developing severe infections like Clostridium difficile (C. diff) and multi-drug resistant bacteria.

Delabeling strategies:

• Utilize clinical decision tools like the PEN-FAST score to assess reaction risk
• Perform penicillin skin testing in a supervised allergist's office
• Conduct a graded oral challenge (test dosing) to safely prove tolerance
• Implement hospital-wide antibiotic stewardship programs to proactively remove false labels

10. Modern biologics and immunotherapy are shifting allergy treatment from symptom management to disease modification.

Allergen immunotherapy (AIT) is the only treatment for allergic rhinitis that works on the underlying cause, which is the abnormal immune response to environmental allergens...

Disease-modifying therapies. Traditional allergy treatments like antihistamines and decongestants only temporarily mask symptoms. In contrast, allergen immunotherapy (AIT)—delivered via allergy shots (SCIT) or sublingual tablets (SLIT)—gradually retrains the immune system to tolerate environmental proteins, providing long-lasting relief and even preventing the development of asthma in children.

The rise of biologics. For patients with severe, uncontrolled allergic diseases, monoclonal antibodies (biologics) offer highly targeted therapy. By blocking specific inflammatory cytokines or receptors (such as IgE, IL-4, IL-5, or IL-13), these lab-grown proteins can dramatically reduce asthma attacks, shrink nasal polyps, clear severe eczema, and protect against accidental food allergen exposures.

Key biologic targets and medications:

• Omalizumab (Xolair): Binds to IgE; treats asthma, chronic hives, and food allergies
• Dupilumab (Dupixent): Blocks IL-4/IL-13; treats eczema, asthma, nasal polyps, and EoE
• Mepolizumab (Nucala) & Benralizumab (Fasenra): Target IL-5 pathways to deplete inflammatory eosinophils
• Tezepelumab (Tezspire): Blocks TSLP at the top of the inflammatory cascade for severe asthma